Malcolm Boyce

3.3k citations
112 papers · 2.5k · h-index 30

Impact in

Papers in

  • Surgery 18
    • Helicobacter pylori-related gastroenterology studies 10
  • Immunology 16
    • Biosimilars and Bioanalytical Methods 7
    • Mast cells and histamine 4
Co-authors
Steve Warrington (30 shared papers)Kathy Baisley (5 shared papers)Peter J. Barnes (4 shared papers)Brian O’Connor (3 shared papers)Trevor T. Hansel (3 shared papers)D. Mark Pritchard (7 shared papers)Stephen T. Holgate (2 shared papers)Andrea Varró (7 shared papers)
Journals
British Journal of Clinical Pharmacology (16 papers)European Journal of Clinical Pharmacology (8 papers)Alimentary Pharmacology & Therapeutics (4 papers)The Journal of Clinical Pharmacology (3 papers)Gastroenterology (3 papers)
Partner nations
United KingdomUnited StatesNorway

In The Last Decade

Malcolm Boyce

106 papers receiving 2.4k citations

Peers

Malcolm Boyce
Comparison fields: 5 of 118
  • Gastroenterology 168
  • Immunology and Allergy 157
  • Physiology 503
  • Immunology 346
  • Oncology 324
Replace Oliviero Sacco with:
Oliviero Sacco Italy
Josep M. Piqué Spain
Kunio Dobashi Japan
Raffaele Manna Italy
Hiromi Iwagaki Japan
François Vrtovsnik France
Tatsuma Okazaki Japan
Gediminas Cepinskas Canada
Noboru Harada Japan
Tetsuo Hayakawa Japan
Malcolm Boyce relative to Oliviero Sacco Italy Oliviero Sacco's profile →
Citations per field
00.5×2×3.2×
Oliviero Sacco · 1×
Citations per year

Countries citing papers authored by Malcolm Boyce

Since Specialization
Citations

This map shows the geographic impact of Malcolm Boyce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Malcolm Boyce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Malcolm Boyce more than expected).

Fields of papers citing papers by Malcolm Boyce

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Malcolm Boyce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Malcolm Boyce. The network helps show where Malcolm Boyce may publish in the future.

Co-authors

The 25 scholars most cited alongside Malcolm Boyce, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Malcolm Boyce Line = papers co-authored together Malcolm Boyce links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 112 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response
The Lancet ·Shannon A. Bryan, Brian O’Connor, Salah Matti, Margaret J Leckie, Varsha Kanabar, Jamey Khan, Steve Warrington, Louis M. Renzetti, Alexis Rames, Juergen A Bock, Malcolm Boyce, Trevor T. Hansel, Stephen T. Holgate, Peter J. Barnes
2000306
2
Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate
Molecular Therapy ·Tracy Zimmermann, Verena Karsten, Amy Chan, Joseph Chiesa, Malcolm Boyce, Brian R. Bettencourt, Renta Hutabarat, Saraswathy V. Nochur, Akshay Vaishnaw, Jared Gollob
2017171
3
Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A
Alimentary Pharmacology & Therapeutics ·Reidar Fossmark, Øystein Sørdal, Constantin S. Jianu, Gunnar Qvigstad, Ivar S. Nordrum, Malcolm Boyce, Helge L. Waldum
201284
4
The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography
Psychopharmacology ·C. J. Bench, Adriaan A. Lammerstma, Paul M. Grasby, Raymond J. Dolan, R. S. J. Frackowiak, SJ Warrington, Malcolm Boyce, K. Gunn, L. Y. Brannick
199675
5
Safety, pharmacokinetics and pharmacodynamics of the anti‐hepcidin Spiegelmer lexaptepid pegol in healthy subjects
British Journal of Pharmacology ·Malcolm Boyce, Steve Warrington, B Cortezi, Stefan Zöllner, S Vauléon, Dorine W. Swinkels, Luciana Summo, Frank Schwoebel, Kai Riecke
201675
6
Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo‐controlled, double‐blind, crossover study
British Journal of Clinical Pharmacology ·Malcolm Boyce, Kathy Baisley, Steve Warrington
201161
7
Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24‐h intragastric pH and serum gastrin in healthy subjects
Alimentary Pharmacology & Therapeutics ·Steve Warrington, Kathy Baisley, Malcolm Boyce, Bina Tejura, Anna Morocutti, Neil Miller
200261
8
Crossover study of the haematological effects and pharmacokinetics of glycosylated and non‐glycosylated G‐CSF in healthy volunteers
British Journal of Haematology ·Michael Watts, Ian E. Addison, S. G. Long, Sigan L. Hartley, Steve Warrington, Malcolm Boyce, David C. Linch
199760
9
Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagus
Oncotarget ·Yoomi Lee, Aleksandra M. Urbanska, Yoku Hayakawa, Hongshan Wang, Andrew S. Au, Aesis Luna, Wenju Chang, Guangchun Jin, Govind Bhagat, Julian A. Abrams, Richard A. Friedman, Andrea Varró, Kenneth K. Wang, Malcolm Boyce, Anil K. Rustgi, Antonia R. Sepulveda, Michael Quante, Timothy C. Wang
201659
10
Netazepide, a gastrin/cholecystokinin‐2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis
British Journal of Clinical Pharmacology ·Malcolm Boyce, Andrew R. Moore, Liv Sagatun, Bryony N. Parsons, Andrea Varró, Fiona Campbell, Reidar Fossmark, Helge L. Waldum, D. Mark Pritchard
201650
11
Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660)
British Journal of Clinical Pharmacology ·Bruce E. Miller, Ruth J. Mayer, Navin Goyal, Joanne Bal, Nigel Dallow, Malcolm Boyce, Donald C. Carpenter, Alison Churchill, Teresa Heslop, Aili L. Lazaar
201748
12
Tolerability, pharmacokinetics and pharmacodynamics of TA‐8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
British Journal of Clinical Pharmacology ·J. Ford, Matt Lawson, D. E. Fowler, Nobuko Maruyama, Seiji Mito, Koichi Tomiyasu, Shuji Kinoshita, Chisa Suzuki, Atsuhiro Kawaguchi, Patrick Round, Malcolm Boyce, Steve Warrington, Werner Weber, Sander van Deventer, John J.P. Kastelein
201447
13
A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition
Journal of Neural Transmission ·Anthony Clarke, E S Johnson, Nicholas Mallard, T. H. Corn, A. E. Johnston, Malcolm Boyce, Steve Warrington, Douglas G MacMahon
200347
14
Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942
EBioMedicine ·Gary Burgess, Malcolm Boyce, Margaret M. Jones, Lars Larsson, Mark Main, Frazer Morgan, P. A. Phillips, Alison Scrimgeour, Foteini Strimenopoulou, Pavan Vajjah, Miren Zamacona, Roger Palframan
201847
15
Netazepide, a Gastrin Receptor Antagonist, Normalises Tumour Biomarkers and Causes Regression of Type 1 Gastric Neuroendocrine Tumours in a Nonrandomised Trial of Patients with Chronic Atrophic Gastritis
PLoS ONE ·Andrew R. Moore, Malcolm Boyce, Islay Steele, Fiona Campbell, Andrea Varró, D. Mark Pritchard
201345
16
Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects
British Journal of Clinical Pharmacology ·Adeep Puri, Andrew Niewiarowski, Yasumasa Arai, H Nomura, Mark E. Baird, Isobel Dalrymple, Steve Warrington, Malcolm Boyce
201745
17
A five way crossover human volunteer study to compare the pharmacokinetics of paracetamol following oral administration of two commercially available paracetamol tablets and three development tablets containing paracetamol in combination with sodium bicarbonate or calcium carbonate
European Journal of Pharmaceutics and Biopharmaceutics ·T. J. Grattan, Rachel Hickman, Anne Darby-Dowman, Marshall A. Hayward, Malcolm Boyce, Steve Warrington
200045
18
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid‐1 Receptor Inverse Agonist, for the Treatment of Obesity: Results From a Double‐Blind, Placebo‐Controlled, Single Oral Dose Study in Healthy Volunteers
The Journal of Clinical Pharmacology ·Carol Addy, Susie Li, Nancy Agrawal, Julie A. Stone, Anup Majumdar, L. Zhong, Hankun Li, Jinyu Yuan, Andrea Maes, Paul Rothenberg, Josée Côté, Kim Rosko, Corinne E Cummings, Steve Warrington, Malcolm Boyce, Keith Gottesdiener, Aubrey Stoch, John A. Wagner
200840
19
Coadministration of Orally Inhaled Zanamivir with Inactivated Trivalent Influenza Vaccine Does Not Adversely Affect the Production of Antihaemagglutinin Antibodies in the Serum of Healthy Volunteers
Clinical Pharmacokinetics ·Alison Webster, Malcolm Boyce, Sally Edmundson, Irene Miller
199939
20
The CCK2 receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development
Regulatory Peptides ·Mark Kidd, Z-L Siddique, Ignat Drozdov, Björn Gustafsson, Robert L. Camp, J.W. Black, Malcolm Boyce, Irvin Modlin
201039

About Malcolm Boyce

Malcolm Boyce is a scholar working on Surgery, Immunology, Molecular Biology, Epidemiology and Physiology, having authored 112 papers that have together received 2.5k indexed citations. Recurring topics across this work include Helicobacter pylori-related gastroenterology studies (10 papers), Asthma and respiratory diseases (9 papers), Neuroendocrine Tumor Research Advances (8 papers), Biosimilars and Bioanalytical Methods (7 papers), Receptor Mechanisms and Signaling (6 papers), Ethics in Clinical Research (5 papers), Gastroesophageal reflux and treatments (4 papers) and Mast cells and histamine (4 papers). The work is most often cited by research in Gastroenterology (168 citations), Immunology and Allergy (157 citations), Physiology (503 citations), Immunology (346 citations) and Oncology (324 citations). Malcolm Boyce has collaborated with scholars based in United Kingdom, United States and Norway. Frequent co-authors include Steve Warrington, Kathy Baisley, Peter J. Barnes, Brian O’Connor, Trevor T. Hansel, D. Mark Pritchard, Stephen T. Holgate, Andrea Varró, Varsha Kanabar and Alexis Rames. Their work appears in journals such as British Journal of Clinical Pharmacology, European Journal of Clinical Pharmacology, Alimentary Pharmacology & Therapeutics, The Journal of Clinical Pharmacology and Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Oliviero SaccoBreakdown of academic impact, for papers by Josep M. PiquéBreakdown of academic impact, for papers by Kunio DobashiBreakdown of academic impact, for papers by Raffaele MannaBreakdown of academic impact, for papers by Hiromi IwagakiBreakdown of academic impact, for papers by François VrtovsnikBreakdown of academic impact, for papers by Tatsuma OkazakiBreakdown of academic impact, for papers by Gediminas CepinskasBreakdown of academic impact, for papers by Noboru HaradaBreakdown of academic impact, for papers by Tetsuo Hayakawa